All In Biotech

NDA 019603 · Otsuka Icu Medcl

Mannitol 15% In Plastic Container

Mannitol · Injection · Osmotic Diuretic

Last checked: Nov 20, 2026Latest source record: Apr 29, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Jan 8, 1987

Approved uses

2

Original approval plus efficacy supplements

Registered trials

387

88 Phase 3, 30 recruiting

FAERS reports

4,906

4,670 serious, 1,418 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2025.

Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema; elevated intraocular pressure. Mannitol Injection is an osmotic diuretic indicated for the reduction of: intracranial pressure and treatment of cerebral edema. ( 1 ) elevated intraocular pressure. ( 1 )

Mechanism: Mannitol, when administered intravenously, exerts its osmotic diuretic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate. This increase in extracellular osmolarity affected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 2020 Supplement 40 · Efficacy LetterLabel
  • Jan 8, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • MANNITOL 15% IN PLASTIC CONTAINER · MANNITOL 15GM/100ML · INJECTABLE, INJECTION · Discontinued
  • MANNITOL 5% IN PLASTIC CONTAINER · MANNITOL 5GM/100ML · INJECTABLE, INJECTION · Discontinued
  • MANNITOL 20% IN PLASTIC CONTAINER · MANNITOL 20GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MANNITOL 10% IN PLASTIC CONTAINER · MANNITOL 10GM/100ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Mannitol" as an intervention, any sponsor and status, largest first.

All 387 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain621
  • renal failure592
  • anxiety502
  • injury495
  • drug ineffective484
  • stress473
  • unevaluable event470
  • fear430
  • death415
  • renal impairment394
  • off label use393
  • emotional distress386

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004116
200579
200689
200759
200887
200973
2010105
2011578
2012255
2013106
2014144
2015123
2016223
2017242
2018215
2019187
2020220
2021304
2022376
2023394
2024395
2025316
2026219

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,010 on PubMed

Sponsor: Otsuka · Also marketed as Mannitol 5% In Plastic Container, Mannitol 20% In Plastic Container, Mannitol 10% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.